×

 

  • ANNOUNCEMENT
  • Public notice

Public notice

Publication Notice

2022-04-27

3,6′- and 1,6′-Dithiopomalidomide Mitigate Ischemic Stroke in Rats and Blunt Inflammation

NEWS PROVIDED BY

Publication Notice

2022-03-02

Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis.

NEWS PROVIDED BY

Publication Notice

2021-07-31

Researches on immunomodulatory imides drug development under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, Int J Mol Sci. (July 31, 2021).

NEWS PROVIDED BY

Publication Notice

2021-04-02

The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, ACS P

NEWS PROVIDED BY

Publication Notice

2021-03-30

Research on the immunomodulatory imide drugs development under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, Frontiers in Neuroscience (March 2

NEWS PROVIDED BY

Chemical Research Center founded at Institut Pasteur Korea, Pan-gyo, Korea

2021-02-01

AevisBio opened Chemical Research Center at Institut Pasteur Korea (IPK) in Pan-gyo, Korea

NEWS PROVIDED BY

AevisBio entered into a collaborative research with NCI

2021-01-15

AevisBio, Inc., a company specializing in developing therapeutics for anti-inflammatory diseases, has entered into a collaborative research with the National Cancer Institute, an institute of the National Institutes of Health (NIH), U.S. Department of Hea

NEWS PROVIDED BY

Patent license agreement with NIH

2021-01-11

Aevisbio and NIH signed the patent license agreement in relation to the development of thalidomide analogues for the treatment of neurological disorders. In accordance of CRADA, Aevisbio and NIH will collaborate to develop the thalidomide analogues in pre

NEWS PROVIDED BY

Korean Government grant awarded from NRF

2021-01-01

Selected a new drug development program including government grant (₩6B) from National Research Foundation of Korea. This program will enable AevisBio to further develop the TPD platform technologies. AevisBio will open the Chemical Research Center at Ins

NEWS PROVIDED BY

Publication Notice

2020-09-14

The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, eLife

NEWS PROVIDED BY Aevisbio, Inc.

AevisBio entered into a collaborative research with KRISS

2020-06-01

In June of 2020, AevisBio and Korea Research Institute of Standards and Science (KRISS) announced a collaboration to develop technologies for treating infectious disease especially focused on COVID19.

NEWS PROVIDED BY

Korean Government grant (post-TIPS) awarded

2020-06-01

Awarded two post-TIPS grants (₩1B each) from Ministry of SMEs and Startups (Korean government).

NEWS PROVIDED BY

South Korea's Most Promising Tech Startups Pitch in the U.S. to Top Investors

2019-10-07

13 Korean Tech Startups Pitch to prominent investors in the Nation's Capital…

NEWS PROVIDED BY Korea Innovation Center Washington DC

AevisBio entered into a CRADA with the NIA, part of the NIH

2019-10-04

AevisBio, Inc., a company specializing in developing therapeutics for anti-inflammatory diseases has entered into a cooperative research and development agreement with the National Institute on Aging (NIA), an institute of the National Institutes of Healt

NEWS PROVIDED BY

Korean Government grant (TIPS) awarded

2019-08-01

Awarded TIPS (Accelerator Investment-Driven Tech Incubator Program for Startup) investment (₩5B) from Ministry of SMEs and Startups (Korean government) with matching fund ($150K) from Bluepoint Partners. The funding will enable AevisBio to further develop

NEWS PROVIDED BY

AevisBio entered into a collaborative research with KRIBB

2019-07-01

In July of 2019, AevisBio and Korea Research Institute of Bioscience & Biotechnology (KRIBB) announced a collaboration to discover, develop, and commercialize therapies for treating disease of aging, including Parkinson’s disease.

NEWS PROVIDED BY

Bio Research Center founded at Bio Venture Center, KRIBB

2019-06-01

AevisBio opened Bio Research Center at BVC, Korea Research Institute of Bioscience and Biotechnology (KRIBB) in Daejeon Korea

NEWS PROVIDED BY

AevisBio, Inc. founded

2018-09-27

2018-09-27 Aevis Bio, Inc, founded in Daejeon, Korea. 2019-04-11 AevisBio, Inc. founded in Gaithersburg, MD USA

NEWS PROVIDED BY